1 domain / 2 areas / 1 specialization
Yale University
Also known as: Yale School of Medicine, Yale University School of Medicine, Yale Department of Psychiatry, Yale University Department of Psychiatry, Yale-New Haven Hospital, Yale University
In 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
Academic Research
0 papersPublished Papers
0
Trial Involvement
21
Distinct Focus Topics
0
Latest Publication
Unknown
Government funding received
2 grantsVA — MDMA-assisted therapy for PTSD + alcohol use disorder in veterans
2024–2029
First VA-funded psychedelic study. VA researchers affiliated with Brown University and Yale University evaluate MDMA-assisted therapy for veterans with both PTSD and alcohol use disorder. $1.5M over five years. Marks the first time since the 1960s the VA has funded research on psychedelic compounds. Attributed here to Yale (Brown isn't in the Blossom stakeholder set).
SourceNIMH K-award — Psilocybin for treatment-resistant OCD (Kelmendi)
2021
First NIMH grant for a psychedelic research investigation since the 1960s. NIH career-development award to Benjamin Kelmendi, MD (Yale School of Medicine) for pilot psilocybin treatment of refractory OCD. Amount ≈$800K.
SourceQuick Facts
- Type
- academic
- HQ
- United States
- Website
- Visit